Tag : II

Dentistry

Long-term safety and efficacy of lanreotide autogel in Japanese patients with neuroendocrine tumors: Final results of a phase II open-label extension study.

Newsemia
Related Articles Long-term safety and efficacy of lanreotide autogel in Japanese patients with neuroendocrine tumors: Final results of a phase II open-label extension study. Asia...
Latest News

Inotrem Receives Clearance From French, Belgian And US Authorities to Launch a Phase II Clinical Trial Aimed at Assessing Nangibotide in Mechanically Ventilated Patients With COVID-19

Newsemia
PARIS–(BUSINESS WIRE)– #PIA–Inotrem launches a Phase II clinical trial to assess nangibotide in Covid-19 patients. Trial will take place in France, Belgium, and the USA....
Latest News

ADC Therapeutics annonce qu’un premier dosage a été déterminé en phase II de l’essai clinique pivot LOTIS 3 du loncastuximab tésirine (Lonca) combiné à l’ibrutinib

Newsemia
LAUSANNE, Suisse–(BUSINESS WIRE)–ADC Therapeutics SA (NYSE:ADCT), une société de biotechnologie spécialisée dans l’oncologie au stade clinique avancé, pionnière du développement et de la commercialisation de...
Pharma / Biotech

The beneficial pharmacological effects and potential mechanisms of picroside II: Evidence of its benefits from in vitro and in vivo.

Newsemia
The beneficial pharmacological effects and potential mechanisms of picroside II: Evidence of its benefits from in vitro and in vivo. Biomed Pharmacother. 2020 Jul 13;130:110421...
Pharma / Biotech

Erlotinib for Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101).

Newsemia
Related Articles Erlotinib for Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101). Oncologist. 2020 Jul 12;: Authors: Nosaki K, Yamanaka T,...
Latest News

The involvement of heat shock protein molecular chaperones in MHC class II antigen processing and presentation

Newsemia
Panjwani, Naveed Nooruddin; (1999) The involvement of heat shock protein molecular chaperones in MHC class II antigen processing and presentation. Doctoral thesis (Ph.D), UCL (University...
Cardiology

Type II Aortopulmonary Window with Isolated Left Subclavian Artery from Left Pulmonary Artery.

Newsemia
Related Articles Type II Aortopulmonary Window with Isolated Left Subclavian Artery from Left Pulmonary Artery. Braz J Cardiovasc Surg. 2020 Jun 01;35(3):402-405 Authors: Agrawal V,...
Biology

NeuroFlow Awarded $750K from the National Science Foundation for SBIR Phase II

Newsemia
PHILADELPHIA (PRWEB) April 17, 2020 NeuroFlow has been awarded $750,000 from the National Science Foundation (NSF) Small Business Innovation Research (SBIR) program to support the...
Latest News

ImmunoGen Presents Initial Data from Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination with Carboplatin and Avastin® at ESMO

Newsemia
WALTHAM, Mass.–(BUSINESS WIRE)–IMGN Presents Initial Data from Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab in Combination with Carboplatin and Avastin® at ESMO Source link...
Biology

A Photosynthesis-Specific Rubredoxin-Like Protein Is Required for Efficient Association of the D1 and D2 Proteins during the Initial Steps of Photosystem II Assembly

Newsemia
Oxygenic photosynthesis relies on accessory factors to promote the assembly and maintenance of the photosynthetic apparatus in the thylakoid membranes. The highly conserved membrane-bound rubredoxin-like...
Pharma / Biotech

Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial.

Newsemia
Related Articles Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World